CCCharlotte Cutler

Charlotte Cutler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Charlotte Cutler has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Detection of Transdermal Application of Testosterone to Racehorses by Analysis of Urine and Plasma

    by Marjaana Viljanto, Charlotte Cutler, Jocelyn Habershon‐Butcher, Pamela Hincks, James Scarth

    The use of testosterone in racehorses is predominantly monitored using international urine and plasma concentration‐based thresholds and complementary steroid ratios. To date, there has been no published pharmacokinetic study on transdermally applied testosterone products in horses and whether their use could result in adverse analytical findings. Therefore, quantitative analysis of testosterone and epitestosterone in urine and testosterone in plasma samples was performed following a pilot multi‐dose transdermal Testogel administration (1 mg/kg once a day for 7 days on clipped skin) to one gelding and one mare. The peak concentrations (C max ) of free testosterone were 1060 and 1800 pg/mL in gelding and mare plasma, respectively. Testosterone concentrations exceeded the international plasma threshold of 100 pg/mL consistently for up to 4 h post‐administration, after which detection above the threshold was sporadic up to 127 h. In urine, C max of free and conjugated (sulfate and glucuronide) testosterone were 700 and 323 ng/mL in gelding and mare urine, respectively. In the gelding, testosterone concentrations exceeded the international urine threshold of 20 ng/mL consistently for up to 47 h post‐administration, but sporadically up to 143 h. In all samples, testosterone: epitestosterone ratios were greater than 5, another requirement for adverse analytical findings in geldings. In the mare, testosterone concentrations exceeded the urine threshold of 55 ng/mL consistently for up to 71 h post‐administration, but sporadically up to 167 h. Therefore, these limited results for one gelding and one mare demonstrate that doping control following transdermal applications of testosterone to racehorses is possible using existing approaches.

  • Detection of the selective androgen receptor modulator S‐23 and its metabolites in equine urine and plasma following oral administration

    by Charlotte Cutler, Marjaana Viljanto, Pamela Hincks, Jocelyn Habershon‐Butcher, James Scarth, Peter van Eenoo

    S‐23 is an arylpropionamide selective androgen receptor modulator that has been investigated in animal models for use as a male hormonal contraceptive but is not yet available therapeutically. S‐23 is available alongside other selective androgen receptor modulators (SARMs) to purchase online via uncontrolled sites, sold as supplement products. It has been detected in several human doping cases, highlighting the importance of identifying the best analytical targets for equine doping control. The purpose of this study was to investigate the detection of S‐23 and its phase I metabolites in equine urine and plasma following a multiple dose oral administration to two Thoroughbred racehorses. Liquid chromatography‐high resolution mass spectrometry was used for metabolite identification, and liquid chromatography–tandem mass spectrometry was used for full sample analysis and generation of urine and plasma profiles. S‐23 and seven phase I metabolites were observed in urine following enzyme hydrolysis and solvolysis. The most abundant analyte detected was the hydroxylated 4‐amino‐2‐(trifluoromethyl)benzonitrile metabolite, which also allowed the longest duration of detection in urine from both horses, for up to 360 h following administration. The data suggest that this metabolite was likely to be highly conjugated with both sulphate and glucuronide moieties. In plasma, S‐23 and two phase I metabolites were observed. S‐23 was the most abundant analyte detected for both horses, allowing detection for up to 143 h post‐administration. To the best of the authors' knowledge, this is the first report of S‐23 and metabolites in equine urine and plasma samples.


  • Detection of FG‐4592 and metabolites in equine plasma, urine and hair following oral administration

    by Charlotte Cutler, Marjaana Viljanto, Polly Taylor, Pamela Hincks, Jocelyn Habershon‐Butcher, Bobby Gray, James Scarth

    FG‐4592 is a hypoxia‐inducible factor inhibitor that has been approved for therapeutic use in some countries. This class of compounds can increase the oxygen carrying capacity of the blood and thus have the potential to be used as performance enhancing agents in sports. The purpose of this study was to investigate the detection of FG‐4592 and metabolites in equine plasma and mane hair following a multiple dose oral administration to two Thoroughbred racehorses, to identify the best analytical targets for doping control laboratories. Urine samples were also analysed, and the results compared to previously published urine data. Liquid chromatography‐high resolution mass spectrometry was used for metabolite identification in urine and plasma. Liquid chromatography–tandem mass spectrometry was used for full sample analysis of urine, plasma and hair samples and generation of urine and plasma profiles. FG‐4592 and a mono‐hydroxylated metabolite were detected in plasma. FG‐4592 was detected with the greatest abundance and gave the longest duration of detection, up to 312 h post‐administration, and would be the recommended target in routine doping samples. FG‐4592 was detected in all mane hair samples collected post‐administration, up to 166 days following the final dose, showing extended detection can be achieved with this matrix. To the best of the authors' knowledge, this is the first report of FG‐4592 and metabolites in equine plasma and hair samples. Urine results were consistent with the previously published data, with FG‐4592 offering the best target for detection and longest detection periods.


  • Detection of the growth hormone secretagogue MK‐0677 in equine hair following oral administration

    by Marjaana Viljanto, Charlotte Cutler, Polly Taylor, Jocelyn Habershon‐Butcher, Bob Gray

    MK‐0677 (ibutamoren) is an orally active non‐peptide growth hormone secretagogue that binds to the ghrelin receptor stimulating the secretion of endogenous growth hormone. It is one of the most prevalent performance‐enhancing compounds currently available online and is potentially subject to abuse both in human and equine sports. The aim of the current study was to investigate whether it could be detected in equine hair following oral administration of MK‐0677 mesylate to a Thoroughbred racehorse. MK‐0677 and its O‐dealkylated metabolite were extracted using an existing method for prohibited substances in equine hair and analysed by liquid chromatography tandem mass spectrometry. This enabled the detection of MK‐0677 in all hair samples collected, up to 209 days in mane and 358 days in tail. A follow‐up methodology with an extensive wash procedure was carried out for selected hair samples, which unambiguously verified the presence of MK‐0677. Wash criteria to differentiate between internal incorporation (via bloodstream) and external deposition (via sweat and sebum) was also assessed and indicated internal incorporation for the samples collected at later time points (≥52 days) and a combination of internal incorporation and external deposition for hair samples collected at the earlier time point (2 days).


  • Equine metabolism of the growth hormone secretagogue MK‐0677 in vitro and in urine and plasma following oral administration

    by Charlotte Cutler, Marjaana Viljanto, Polly Taylor, Jocelyn Habershon‐Butcher, Peter Van Eenoo

    Ibutamoren mesylate, or MK‐0677, is an orally active, nonpeptide growth hormone secretagogue that has been developed to stimulate excretion of endogenous growth hormone. It has been evaluated for the treatment of a range of clinical conditions but is not available therapeutically. Nonetheless, MK‐0677 is widely available to purchase online, sold as ‘supplement’ products. The mode of action and relative ease of purchase make MK‐0677 a potential threat with regard to sports doping. The aim of this study was to investigate the metabolism of MK0677 in the horse following in vitro incubation and oral administration to two Thoroughbred racehorses, in order to identify the most appropriate analytical targets for doping control laboratories. Liquid chromatography high resolution mass spectrometry was used for metabolite identification, and subsequently, liquid chromatography–tandem mass spectrometry was used to generate full metabolite profiles for post‐administration urine and plasma samples. Fourteen phase I metabolites were identified in vitro; 13 of these were subsequently detected in urine and nine in plasma collected post‐administration, alongside the parent compound in both matrices. In both urine and plasma, the longest duration of detection was observed for an O‐dealkylated metabolite of MK‐0677, and therefore, this would be the best target for the detection of MK‐0677 administration. MK‐0677 and the O‐dealkylated metabolite were found to be excreted largely unconjugated in urine and plasma.


  • Identification of equine in vitro metabolites of seven non‐steroidal selective androgen receptor modulators for doping control purposes

    by Charlotte Cutler, Marjaana Viljanto, Polly Taylor, Pamela Hincks, Simon Biddle, Peter Van Eenoo

    Selective androgen receptor modulators, SARMs, are a large class of compounds developed to provide therapeutic anabolic effects with minimal androgenic side effects. A wide range of these compounds are available to purchase online, and thus provide the potential for abuse in sports. Knowledge of the metabolism of these compounds is essential to aid their detection in doping control samples. In vitro models allow a quick, cost-effective response where administration studies are yet to be carried out. In this study, the equine phase I metabolism of the non-steroidal SARMs GSK2881078, LGD-2226, LGD-3303, PF-06260414, ACP-105, RAD-140 and S-23 was investigated using equine liver microsomes. Liquid chromatography coupled to a QExactive Orbitrap mass spectrometer allowed identification of metabolites with high resolution and mass accuracy. Three metabolites were identified for both GSK2881078 and LGD-2226, four for LGD-3303 and RAD-140, five for PF-06260414, twelve for ACP-105 and ten for S-23. The equine metabolism of GSK-2881078, LGD-2226, LGD-3303 and PF-06260414 is reported for the first time. Although the equine metabolism of ACP-105, RAD-140 and S-23 has previously been reported, the results obtained in this study have been compared with published data.


  • In vitro and in vivo metabolism of the anabolic‐androgenic steroid oxandrolone in the horse

    by Caitlin Harding, Marjaana Viljanto, Charlotte Cutler, Jocelyn Habershon‐Butcher, Simon Biddle, James Scarth

    Oxandrolone is an anabolic‐androgenic steroid with favourable anabolic to androgenic ratio, making it an effective anabolic agent with less androgenic side effects. Although its metabolism has been studied in humans, its phase I and II metabolism has not been previously reported in the horse. The purpose of this study was to investigate the in vitro metabolism of oxandrolone (using both equine liver microsomes and S9) and in vivo metabolism following oral administration (three daily doses of 50 mg of oxandrolone to a single Thoroughbred horse), using both gas and liquid chromatography‐mass spectrometry techniques. The in vitro phase I transformations observed included 16‐hydroxylated (two epimers), 17‐methyl‐hydroxylated and 16‐keto metabolites. In addition to parent oxandrolone and these hydroxylated metabolites, the 17‐epimer and a 17,17‐dimethyl‐18‐norandrost‐13‐ene analogue were detected in biological samples following the administration. 16‐keto‐oxandrolone was only observed in urine. The 16‐ and 17‐methyl‐hydroxylated oxandrolone metabolites were predominantly excreted as sulfate conjugates in urine, whereas parent oxandrolone, its epimer and 17,17‐dimethyl‐18‐norandrost‐13‐ene derivative were found predominantly in the unconjugated urine fraction. The most abundant analyte detected in both plasma and urine was parent oxandrolone. However, the longest detection period using the developed analytical method was provided by 17‐hydroxymethyl‐oxandrolone in both matrices. The results of this study provided knowledge of how best to detect the use of oxandrolone in regulatory samples.


  • In vitro metabolism of the REV‐ERB agonist SR‐9009 and subsequent detection of metabolites in associated routine equine plasma and urine doping control samples

    by Charlotte Cutler, Daniel Leigh White, Marjaana Viljanto

    SR‐9009 is a synthetic compound widely available to purchase online as ‘supplement’ products due to its potential performance‐enhancing effects, presenting a significant threat with regard to doping control in sport. In vitro metabolism with equine liver microsomes was performed to identify potential targets for detection of SR‐9009. Six metabolites were identified, with the most abundant consisting of N‐dealkylated metabolites (M1–M3). The addition of the identified metabolites to high‐resolution accurate mass databases resulted in a positive finding for the N‐dealkylated metabolite M1 of SR‐9009 in an associated plasma and urine doping sample. Liquid chromatography–high‐resolution mass spectrometry was used to verify the presence of the N‐dealkylated metabolite (M1) in both matrices, with a low concentration of the parent compound and additional N‐desalkyl metabolites (M2 and M3) detected in the plasma sample as supporting evidence of administration. To the best of the authors' knowledge, this is the first report of an adverse analytical finding in an equine sample for SR‐9009 or its metabolites in equine doping control.


  • Equine metabolism of the selective androgen receptor modulator AC‐262536 in vitro and in urine, plasma and hair following oral administration

    by Charlotte Cutler, Marjaana Viljanto, Polly Taylor, Jocelyn Habershon‐Butcher, Tessa Muir, Simon Biddle, Peter Van Eenoo

    AC‐262536 is one of a number of selective androgen receptor modulators that are being developed by the pharmaceutical industry for treatment of a range of clinical conditions including androgen replacement therapy. Though not available therapeutically, selective androgen receptor modulators are widely available to purchase online as (illegal) supplement products. The growth‐ and bone‐promoting effects, along with fewer associated negative side effects compared with anabolic–androgenic steroids, make these compounds a significant threat with regard to doping control in sport. The aim of this study was to investigate the metabolism of AC‐262536 in the horse following in vitro incubation and oral administration to two Thoroughbred horses, in order to identify the most appropriate analytical targets for doping control laboratories. Urine, plasma and hair samples were collected and analysed for parent drug and metabolites. Liquid chromatography–high‐resolution mass spectrometry was used for in vitro metabolite identification and in urine and plasma samples. Nine phase I metabolites were identified in vitro; four of these were subsequently detected in urine and three in plasma, alongside the parent compound in both matrices. In both urine and plasma samples, the longest detection window was observed for an epimer of the parent compound, which is suggested as the best target for detection of AC‐262536 administration. AC‐262536 and metabolites were found to be primarily glucuronide conjugates in both urine and plasma. Liquid chromatography–tandem mass spectrometry analysis of post‐administration hair samples indicated incorporation of parent AC‐262536 into the hair following oral administration. No metabolites were detected in the hair.


  • Investigations into the analysis of intact drug conjugates in animal sport doping control – Development and assessment of a rapid and economical approach for screening greyhound urine

    by Bob Gray, Lisa Tuckley, Charlotte Cutler, Simon Biddle, Simon Hudson, Simon Gower, Lynn Vanhaecke

    Animal sport doping control laboratories are constantly reviewing ways in which they can improve their service offering whilst ensuring to remain economically viable. This paper describes the development and assessment of a rapid and economical method for the detection of intact glucuronide conjugates of three anabolic steroids and their metabolites along with three corticosteroids in canine urine. The analysis of intact drug conjugates for animal sport doping control is generally not performed routinely as it presents a number of analytical challenges, not least of which is the lack of availability of appropriate reference standards. Here, we report the development of a UHPLC‐MS/MS method using APCI in the negative ion mode for the detection of intact phase II conjugates, including the importance of in vitro incubations in order to provide appropriate reference materials. Cross‐validation of the developed method demonstrated that detection capability of the intact phase II conjugates of stanozolol, boldenone, nandrolone and their metabolites along with the corticosteroids dexamethasone and methylprednisolone was equivalent to that achieved in routine race‐day screens. The new process has been in operation for approximately 2 years and has been used to analyse in‐excess of 13,500 canine urine samples, resulting in a number of positive screening findings. To the best of our knowledge, this is the first reported use of a routine screen for intact drug conjugates within animal sport doping control.